{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:25:45Z","timestamp":1794410745230,"version":"4.9.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurology and Neurosurgery"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.clineuro.2023.107612","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T11:26:42Z","timestamp":1674473202000},"page":"107612","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Discontinuation of disease-modifying therapy in MS patients over 60 years old and its impact on relapse rate and disease progression"],"prefix":"10.1016","volume":"225","author":[{"given":"Manuel","family":"Salavisa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipa","family":"Serrazina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Filipa","family":"Ladeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Sofia","family":"Correia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clineuro.2023.107612_bib1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clineuro.2023.107612_bib2","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/B978-0-444-52001-2.00014-5","article-title":"The clinical course of multiple sclerosis","volume":"122","author":"Confavreux","year":"2014","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.clineuro.2023.107612_bib3","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41582-019-0183-3","article-title":"Epidemiology and treatment of multiple sclerosis in elderly populations","volume":"15","author":"Vaughn","year":"2019","journal-title":"Nat. Rev. Neurol."},{"issue":"3","key":"10.1016\/j.clineuro.2023.107612_bib4","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/brain\/awl007","article-title":"Natural history of multiple sclerosis: a unifying concept","volume":"129","author":"Confavreux","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.clineuro.2023.107612_bib5","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1136\/jnnp.2008.145805","article-title":"Relapses in multiple sclerosis are age- and time-dependent","volume":"79","author":"Tremlett","year":"2008","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.clineuro.2023.107612_bib6","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nrneurol.2012.168","article-title":"Progressive multiple sclerosis: pathology and pathogenesis","volume":"8","author":"Lassmann","year":"2012","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.clineuro.2023.107612_bib7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1212\/WNL.0000000000001094","article-title":"Relapses and disability accumulation in progressive multiple sclerosis","volume":"84","author":"Paz Soldan","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2023.107612_bib8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11910-017-0771-9","article-title":"Immunosenescence: the role of aging in the predisposition to neuro-infectious complications arising from the treatment of multiple sclerosis","volume":"17","author":"Grebenciucova","year":"2017","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.clineuro.2023.107612_bib9","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/ni.2588","article-title":"Understanding immunosenescence to improve responses to vaccines","volume":"14","author":"Goronzy","year":"2013","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.clineuro.2023.107612_bib10","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.smim.2012.04.008","article-title":"Innate immunosenescence: effect of aging on cells and receptors of the innate immune system in humans","volume":"24","author":"Solana","year":"2012","journal-title":"Semin Immunol."},{"key":"10.1016\/j.clineuro.2023.107612_bib11","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40266-019-00741-1","article-title":"Informing medication discontinuation decisions among older adults with relapsing-onset multiple sclerosis","volume":"37","author":"Schwehr","year":"2020","journal-title":"Drugs Aging"},{"key":"10.1016\/j.clineuro.2023.107612_bib12","article-title":"Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60","author":"Hua","year":"2018","journal-title":"Mult. Scler."},{"issue":"7","key":"10.1016\/j.clineuro.2023.107612_bib13","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1212\/01.WNL.0000156155.19270.F8","article-title":"Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity","volume":"64","author":"Roxburgh","year":"2005","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.clineuro.2023.107612_bib14","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1002\/acn3.771","article-title":"Plasma proteome in multiple sclerosis disease progression","volume":"6","author":"Malekzadeh","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"9157","key":"10.1016\/j.clineuro.2023.107612_bib15","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/S0140-6736(98)03053-0","article-title":"Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group","volume":"353","author":"Kappos","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.clineuro.2023.107612_bib16","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/jnnp.62.3.285","article-title":"Gadolinium-enhanced MRI predicts clinical and MRI disease activity in relapsing\u2013remitting multiple sclerosis","volume":"67","author":"Koudriatseva","year":"1997","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.clineuro.2023.107612_bib17","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1093\/brain\/awz156","article-title":"Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis","volume":"142","author":"Brownlee","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.clineuro.2023.107612_bib18","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/ene.12690","article-title":"Subgroups of multiple sclerosis patients with larger treatment benefits: a meta-analysis of randomized trials","volume":"22","author":"Signori","year":"2015","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.clineuro.2023.107612_bib19","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1177\/1352458516675751","article-title":"Discontinuation of disease-modifying therapies in multiple sclerosis\u2013 Clinical outcome and prognostic factors","volume":"23","author":"Bsteh","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.clineuro.2023.107612_bib20","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s00415-015-7986-y","article-title":"Optimizing treatment success in multiple sclerosis","volume":"263","author":"Ziemssen","year":"2016","journal-title":"J. Neurol."},{"key":"10.1016\/j.clineuro.2023.107612_bib21","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1474-4422(14)70256-X","article-title":"Pathological mechanisms in progressive multiple sclerosis","volume":"14","author":"Mahad","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.clineuro.2023.107612_bib22","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1136\/jnnp-2016-313760","article-title":"Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity scorematched study","volume":"87","author":"Kister","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.clineuro.2023.107612_bib23","doi-asserted-by":"crossref","first-page":"11","DOI":"10.7224\/1537-2073.2015-032","article-title":"Stopping disease-modifying therapy in nonrelapsing multiple sclerosis","volume":"19","author":"Birnbaum","year":"2017","journal-title":"Int. J. MS Care"},{"key":"10.1016\/j.clineuro.2023.107612_bib24","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1177\/1352458509351730","article-title":"Discontinuing disease-modifying therapy in progressive multiple sclerosis: Can we stop what we have started?","volume":"15","author":"Lonergan","year":"2009","journal-title":"Mult. Scler."},{"key":"10.1016\/j.clineuro.2023.107612_bib25","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.msard.2017.01.009","article-title":"Discontinuation of disease modifying treatments in middle aged multiple sclerosis patients.\u00a0First line drugs vs natalizumab","volume":"12","author":"Fagius","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.clineuro.2023.107612_bib26","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2165\/11532120-000000000-00000","article-title":"Multiple sclerosis in the elderly patient","volume":"27","author":"Awad","year":"2010","journal-title":"Drugs Aging"}],"container-title":["Clinical Neurology and Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846723000288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846723000288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T14:44:22Z","timestamp":1759589062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303846723000288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":26,"alternative-id":["S0303846723000288"],"URL":"https:\/\/doi.org\/10.1016\/j.clineuro.2023.107612","relation":{},"ISSN":["0303-8467"],"issn-type":[{"value":"0303-8467","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discontinuation of disease-modifying therapy in MS patients over 60 years old and its impact on relapse rate and disease progression","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurology and Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clineuro.2023.107612","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107612"}}